fbpx Skip to main content

THURSDAY, Feb. 11, 2021 (HealthDay News) — Individuals with overweight or obesity receiving once-weekly subcutaneous semaglutide plus lifestyle intervention achieved sustained, clinically relevant reductions in body weight, according to a study published online Feb. 10 in the New England Journal of Medicine.

John P. H. Wilding, D.M., from the University of Liverpool in the United Kingdom, and colleagues enrolled 1,961 adults with a body mass index of 30 or greater who did not have diabetes and randomly assigned them to 68 weeks of either once-weekly subcutaneous semaglutide or placebo plus lifestyle intervention in a 2:1 ratio.

The researchers found that the mean change in body weight from baseline to week 68 was −14.9 and −2.4 percent in the semaglutide and placebo groups, respectively, for an estimated treatment difference of −12.4 percent. At week 68, compared with the placebo group, more participants in the semaglutide group achieved weight loss of 5 percent or more (86.4 versus 31.5 percent), 10 percent or more (69.1 versus 12.0 percent), and 15 percent or more (50.5 versus 4.9 percent). With respect to cardiometabolic risk factors, participants who received semaglutide had greater improvement than those receiving placebo. The most common adverse events with semaglutide were nausea and diarrhea, which were typically transient, were mild to moderate in severity, and decreased with time.

“The STEP 1 trial (like its name) is a good beginning,” write the authors of an accompanying editorial. “However, as noted by the authors, there are concerns, including adverse events.”

The study was funded by Novo Nordisk, the manufacturer of semaglutide.

Abstract/Full Text (subscription or payment may be required)

You May Also Like::  Meds for Enlarged Prostate Tied to Heart Failure Risk

Editorial (subscription or payment may be required)

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More